文献速递主动脉疾病血液透析通路

慢性肾脏替代治疗患者择期EVAR结局:两国数据链接研究

Outcomes of elective endovascular aneurysm repair in patients receiving chronic kidney replacement therapy from a binational data linkage study.
PubMed 文献 · J Vasc Surg · 2025-07-17

该研究通过澳大利亚与新西兰透析移植登记库(ANZDATA)与州级健康数据链接,识别2000至2015年间接受慢性肾脏替代治疗(KRT)并因肾下腹主动脉瘤行EVAR的患者。择期EVAR 30天死亡率为2.7%,12个月死亡率为18.3%,血液透析患者30天风险最高(4.2%),提示该人群择期EVAR后疾病负担高,需在共享决策中权衡风险与获益。

要点

  • 择期EVAR后30天死亡率为2.7%,12个月死亡率达18.3%。
  • 血液透析患者30天死亡率最高,为4.2%。
  • 术后感染性并发症比心血管并发症更常见。

核心结论

  • 慢性KRT患者择期EVAR后发病率和死亡率高,应在共享决策及评估风险获益时加以考虑。

研究设计与样本

  • 回顾性两国数据链接研究,链接ANZDATA与州级健康数据集,纳入2000年1月1日至2015年12月31日接受慢性KRT并因AAA行EVAR的患者。
  • 共367例患者接受397次EVAR,其中择期216次(54%)、急诊181次(46%),按KRT模式分为HD、PD、HHD和KT,采用logistic回归分析30天和12个月死亡率及非致命并发症。

主要发现

  • 择期EVAR发生率为每100患者年0.25次,多数病例(51%)见于HD患者。
  • 择期EVAR后30天死亡率为2.7%(95%CI 0.4-5.1),HD患者风险最高为4.2%(95%CI 0.4-8.0)。
  • 择期EVAR后12个月死亡率全队列为18.3%(95%CI 13.1%-23.4%),HD与PD患者风险大致相当。
  • 术后感染性并发症比心血管并发症更常见。
  • 急诊EVAR后所有不良结局的发生频率均高于择期EVAR。

临床怎么用

  • 对慢性KRT合并AAA患者行择期EVAR前,应结合其30天及12个月死亡风险进行共享决策。
  • 血液透析患者择期EVAR后30天死亡风险较高,围手术期需加强评估与监护。
  • 术后应关注感染性并发症,其发生频率高于心血管并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our study aims to define the rates of mortality and nonfatal complications in patients with kidney failure undergoing elective endovascular aortic aneurysm repair (EVAR) for the management of infrarenal abdominal aortic aneurysm (AAA) in Australia and New Zealand. METHODS: A retrospective binational data linkage between the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) and state-based health-related datasets identified patients receiving chronic kidney replacement therapy (KRT) who underwent EVAR for AAA between January 1, 2000, and December 31, 2015. Linked data were interrogated to define patient demography, modality of KRT, date of death, and the occurrence of specific nonfatal complications. Patients were categorized by modality (hemodialysis [HD], peritoneal dialysis [PD], home hemodialysis [HHD], and kidney transplant [KT]), and logistic regression analysis was used to determine the rates of 30-day and 12-month mortality, as well as nonfatal postoperative complications. RESULTS: During the study period, 367 patients receiving KRT underwent 397 EVAR procedures for AAAs. Of these, 216 (54%) were performed electively, and 181 (46%) were performed emergently. The rate of elective EVAR was 0.25 per 100 patient-years, with the majority of cases (51%) occurring in patients receiving HD. Overall, 30-day mortality following elective EVAR was 2.7% (95% confidence interval [CI], 0.4-5.1), with HD patients being at greatest risk at 4.2% (95% CI 0.4-8.0). Postoperative infective complications were more common than cardiovascular complications. Twelve-month mortality following elective EVAR was 18.3% (95% CI, 13.1%-23.4%) for the entire cohort, with HD and PD patients being at approximately equivalent risk. All adverse outcomes were observed with greater frequency following emergency EVAR compared with those undertaken electively. CONCLUSIONS: Patients on chronic KRT have high rates of morbidity and mortality following elective EVAR. This should be accounted for during shared decision-making and when considering the relationship between risk and benefit in the management of AAAs in this population.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hinde D, Palamuthusingam D, Hawley CM, et al. Outcomes of elective endovascular aneurysm repair in patients receiving chronic kidney replacement therapy from a binational data linkage study. J Vasc Surg. 2025. PMID: 40683394. doi:10.1016/j.jvs.2025.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。